Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC By Ogkologos - May 19, 2026 144 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic December 20, 2022 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ January 17, 2022 Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of... December 6, 2022 “World’s Tiniest Baby” Has Been Released From The Hospital March 8, 2019 Load more HOT NEWS FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... 癌症可以在家族成员中被遗传吗？ Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Trialling a new way to boost CAR T-cell therapy
